生物技术

Synthetic Biology and the Bio-Manufacturing Industry’s Innovation Drivers for 2025: The Advent of AI Integration and Mass Production Era

Editor
8 分钟阅读

As of the end of 2025, the synthetic biology industry is experiencing unprecedented growth, establishing itself as a key driver in the biotechnology ecosystem. The global synthetic biology market reached $42 billion in 2025, with a compound annual growth rate (CAGR) of 23.7%, and is expected to expand to a $120 billion market by 2030. This rapid growth is the result of a combination of factors, including the maturation of AI-based protein design technology, the commercialization of automated bio-manufacturing platforms, and the increasing demand for sustainable bio-based chemicals. Particularly in 2025, the application of large language models like ChatGPT in the biological field has accelerated, leading to innovative changes where the development process of microbial strains, which traditionally took years, is now reduced to months.

Synthetic Biology and the Bio-Manufacturing Industry’s Innovation Drivers for 2025: The Advent of AI Integration and Mass Production Era

Korean bio-manufacturing companies are at the forefront of this transformation. Samsung Biologics, headquartered in Songdo, Incheon, maintained its leading position with a 28.4% market share in the global biopharmaceutical contract development and manufacturing organization (CDMO) market as of the fourth quarter of 2025. The company secured new contracts worth a total of $19.5 billion this year, 42% of which are related to synthetic biology-based next-generation biopharmaceutical production projects. Samsung Biologics’ fourth plant, completed in March 2025, has an annual production capacity of 240,000L and generates an average monthly revenue of $1.2 billion through its dedicated cell and gene therapy (CGT) production line. The company’s integrated R&D center within the Songdo Bio Cluster has achieved a 34% improvement in production yield on average by adopting an AI-based bio-process optimization system.

Technological Innovations in AI-Integrated Bio-Manufacturing Platforms

Ginkgo Bioworks, based in Boston, USA, has emerged as the most notable platform company in the synthetic biology field in 2025. The company’s “biological foundry” system combines AI and automated robotics to provide an integrated platform for designing and testing custom microorganisms in large quantities. As of the third quarter of 2025, Ginkgo’s platform can simultaneously test an average of 15,000 microbial strains daily, and its machine learning algorithms prioritize designs with higher success probabilities, reducing development costs by 67% compared to traditional methods. The company recorded an annual revenue of $423 million in 2025, with 62% of it coming from licensing revenue through partnerships with pharmaceutical companies. Ginkgo’s proprietary “Codebase” system currently holds over 84 million DNA sequence data, achieving innovation by reducing the development time for new bio-products from an average of 18 months to 7 months.

Novozymes, headquartered in Copenhagen, Denmark (currently listed in the US), maintains a unique position in the enzyme-based bio-solution field and is expanding its business scope through synthetic biology technology. In 2025, the proportion of new enzyme products based on synthetic biology in the company’s total revenue of $2.4 billion increased to 31%, showing strong growth particularly in the laundry enzyme and biofuel enzyme sectors. Novozymes’ AI-based enzyme design platform “BioZyme AI” developed a total of 847 new enzyme variants in 2025, with 78% achieving performance improvements over existing products. The company is particularly focused on producing bio-based chemicals for carbon neutrality, supplying products that achieve an annual CO2 reduction effect of 12.4 million tons as of 2025.

Amyris, headquartered in Emeryville, California, is a leader in the field of sustainable material production using synthetic biology, showing innovative results in the cosmetics, fragrance, and biofuel markets in 2025. The company’s proprietary yeast-based fermentation platform currently has the capacity to produce 500,000 tons of bio-based chemicals annually, achieving an average 85% reduction in carbon emissions compared to conventional petrochemical-based production. Amyris recorded a total revenue of $684 million as of the third quarter of 2025, with 73% coming from its B2B raw material supply business. The company’s flagship products, squalene and bio-based fragrance ingredients, have secured a stable revenue base through long-term supply contracts with global consumer goods companies like P&G and Unilever.

Another major player in the Korean biopharmaceutical market, Celltrion, is accelerating the adoption of synthetic biology technology while maintaining its global leadership in the biosimilar field, centered around its headquarters in Yeonsu-gu, Incheon. The company’s annual revenue in 2025 was $2.8 billion, with 64% coming from overseas sales. Celltrion’s Songdo Plant 2 aims to reduce the development period for new biosimilars from the current 5-7 years to 3-4 years by fully implementing an AI-based cell line development system from the second half of 2025. The company is actively utilizing synthetic biology technology for the development of next-generation antibody-drug conjugates (ADCs), with 12 ADC candidates in the preclinical stage as of the end of 2025.

Market Segmentation and Competitive Landscape Analysis

In 2025, the synthetic biology market shows clear segmentation by application field. The medical sector accounts for the largest share at 43% of the total market, valued at $18 billion, followed by chemicals and materials (26%, $10.9 billion), agriculture and food (18%, $7.6 billion), and energy and environment (13%, $5.5 billion). In the medical field, the development of personalized cell and gene therapies is rapidly expanding, with a total of 47 synthetic biology-based therapies approved by the FDA as of 2025. Among these, CAR-T cell therapies account for 19, gene-editing-based therapies for 12, and synthetic biological vaccines for 16.

In the chemicals and materials sector, bio-based plastics and sustainable chemical raw material production are major growth drivers. The global bioplastics market grew to $16.4 billion in 2025, with products utilizing synthetic biology technology accounting for 32%. DSM, headquartered in Delft, Netherlands (now merged with Swiss Firmenich), leads in the production of synthetic biology-based biopolymers, recording $1.2 billion in revenue in this segment alone in 2025. In the agriculture sector, customized microbial fertilizers and biopesticides are rapidly growing, with a total of 134 synthetic biology-based agricultural products approved by the USDA as of 2025.

In terms of regional market analysis, North America forms the largest market at 47% of the total, valued at $19.7 billion, followed by Europe at 28% ($11.8 billion) and Asia-Pacific at 21% ($8.8 billion). The Asia-Pacific region is experiencing the fastest growth with a CAGR of 28.4%, driven by large-scale government investments in China and Korea and technological innovations in Japan. The Chinese government invested a total of $4.7 billion in the synthetic biology sector in 2025, with 60% focused on building bio-manufacturing infrastructure. Korea also invested $1.6 billion through the K-Bio Belt project in 2025 to significantly enhance the synthetic biology capabilities of the Osong, Daedeok, and Songdo Bio Clusters.

Analyzing venture capital investment trends, the global investment in synthetic biology startups reached a total of $8.9 billion in 2025, a 34% increase from the previous year. Series A stage investments accounted for the largest share at 41%, with an average investment size of $23.4 million. Notably, overseas investment in Korean synthetic biology startups has significantly increased. In 2025, Korean biotech startups attracted a total of $1.2 billion in overseas investments, with 35% concentrated in synthetic biology-related companies. Particularly, Syntekabio, headquartered in Gangnam-gu, Seoul, raised $85 million in a Series B round in September 2025, accelerating the global expansion of its AI-based drug development platform.

The status of synthetic biology patent applications also serves as an important indicator of the industry’s pace of innovation. In 2025, the total number of synthetic biology-related patent applications worldwide was 18,432, a 42% increase from the previous year. By country, the United States ranked first with 6,847 applications (37.2%), followed by China with 4,923 (26.7%), Japan with 2,156 (11.7%), and Germany with 1,834 (10.0%). Korea ranked fifth with 1,247 applications (6.8%), but demonstrated qualitative excellence with an average citation per patent of 12.4, surpassing the United States (11.8). Particularly, Korean bio-manufacturing-related patents have an average citation of 18.7, indicating a significant technological impact.

Changes in the regulatory environment also have a significant impact on industry development. In March 2025, the US FDA announced new guidelines for synthetic biology products, simplifying approval procedures and accelerating the market entry of innovative therapies. Consequently, the total number of synthetic biology-based pharmaceuticals approved by the FDA in the second half of 2025 was 23, an 85% increase from the same period the previous year. The European Medicines Agency (EMA) also showed similar movements, introducing an adaptive pathway for synthetic biology products in June 2025. Korea’s Ministry of Food and Drug Safety (MFDS) established an Advanced Biopharmaceutical Integrated Review Center in January 2025, reducing the approval review period for synthetic biology-based therapies from the previous 18 months to 12 months.

The main challenges facing the synthetic biology industry in 2025 include increasing technological complexity and quality control issues in mass production. Reducing the gap between AI-based design and actual biological implementation is recognized as a key challenge. Currently, the rate at which AI-predicted protein functions operate as expected in actual experiments is about 67%, and continued R&D investment is being made to improve this to over 90%. Additionally, standardizing processes to minimize batch-to-batch quality variations in the mass production of synthetic biology products is a critical issue. Leading companies like Samsung Biologics have achieved a 99.8% level of quality consistency by introducing real-time quality monitoring systems and AI-based process optimization algorithms to address this issue.

As of the end of 2025, the synthetic biology industry has reached a critical turning point in terms of technological maturity and commercial viability. The integration of AI and automation technologies has significantly improved development speed and success rates, and practical solutions are emerging across various industrial sectors based on large-scale investments and policy support. Particularly, the combination of Korean companies’ bio-manufacturing capabilities and global companies’ platform technologies is expanding opportunities for new value creation. Over the next 3-5 years, synthetic biology is expected to fundamentally change existing industrial structures in the medical, chemical, agricultural, and energy sectors, with companies possessing both technological innovation and commercialization capabilities leading the market.

*This analysis is based on publicly available market data and company announcements, and additional due diligence and expert consultation are recommended before making investment decisions.*

#Samsung Biologics #Celltrion #Ginkgo Bioworks #Zymergen #(Acquired by Ginkgo) Moderna #Novozymes #Amyris

Editor

Leave a Comment

Related Articles

合成生物学与生物制造的创新浪潮:2026年生物技术产业的新转折点

随着合成生物学技术的成熟,生物制造市场正在迅速扩展,正在形成替代传统化学工艺的新范式。截至2026年,全球生物制造市场以年均12.3%的增长率达到5,420亿美元的规模。

生物技术创新的新转折点:AI驱动的新药开发与精准医学描绘的2025年产业格局

2025年,生物技术产业正通过人工智能与精准医学的融合进入新的增长轨道。全球生物制药市场规模突破6,850亿美元,AI驱动的新药开发平台将传统10-15年的开发周期缩短至5-7年,引领创新。

生物技术创新的新篇章:2025年基于AI的新药开发与基因治疗的快速增长

AI驱动的新药开发引领生物技术创新 2025年,全球生物技术行业因全面引入人工智能和机器学习技术而迎来新的转折点。根据市场调研机构麦肯锡的最新报告,预计2025年全球生物技术市场规模将达到1.24万亿美元,同比增长18.7%。特别是AI驱动的新药开发领域以42.3%的年均增长率引领整个生物技术市场的增长。这一快速增长的背景在于AI技术的创新性发展,使传统新药开发所需的10-15年开发周期缩短至5-7年。 总部位于美国加州旧金山的Genentech与瑞士巴塞尔的Roche共同开发的AI平台“pRED”自2024年第四季度商业化以来,已发现73种新药候选物质。这一速度是传统方法的3.2倍,业内专家称其为“新药开发范式的根本性变化”。与此同时,英国剑桥的DeepMind开发的AlphaFold3将蛋白质结构预测准确度提高到95.8%,全球制药公司正加速利用这一技术进行新药开发。在韩国,三星生物制剂宣布自2025年第二季度起,通过自主开发的AI平台“SamBio-AI”将抗体药物开发流程缩短了40%。 基因治疗与细胞治疗市场的扩展 2025年,基因治疗市场呈现爆炸性增长。预计全球基因治疗市场规模将从2024年的167亿美元增长至2025年的242亿美元,增幅达44.9%。这一增长归因于CRISPR-Cas9技术的高度化和CAR-T细胞治疗应用范围的扩大。特别是在罕见病和癌症治疗领域,基因治疗的临床成功率大幅提升,吸引了投资者的关注。 总部位于瑞士巴塞尔的诺华公司(Novartis)的CAR-T细胞治疗药物Kymriah在2025年上半年实现全球销售额18亿美元,同比增长127%。美国FDA批准的CAR-T治疗药物现已达到12种,其中8种是在2024年后获得批准的。在韩国,Celltrion自主开发的CAR-T治疗药物“CT-P1”于今年3月获得韩国食品药品安全部的临床三期批准,向商业化迈进了一步。Celltrion预计通过这一治疗药物,到2027年实现年销售额5000亿韩元。 韩国的K-生物带政策在基因治疗领域的发展中也发挥了重要作用。政府宣布的“K-生物大挑战”项目总预算为2.3万亿韩元,其中40%即9200亿韩元集中投入基因治疗的研究开发。Osong生物集群目前有143家生物企业入驻,预计这些企业在2025年的累计销售额将达到4.12万亿韩元,同比增长34.7%。特别是基因治疗专业企业的增长尤为显著,Genexine的基因治疗药物开发相关销售额同比增长156%。 国际上对基因治疗的投资也在急剧增加。2025年1月至11月,全球基因治疗初创公司的风险投资总额达到87亿美元,已超过2024年全年投资额的40%。在美国,NIH(国家卫生研究院)为基因治疗研究分配了2025年预算34亿美元,欧盟也通过Horizon Europe计划投入28亿欧元。中国也作为第十四个五年计划的一部分,每年在基因治疗领域投资15亿美元,全球竞争愈发激烈。 生物技术行业的另一个主要趋势是个性化医疗(精准医疗)的普及。通过分析个人的遗传信息提供优化治疗方案的精准医疗市场在2025年已增长至1240亿美元,保持13.8%的年均增长率。美国Illumina的下一代测序(NGS)技术商业化后,个人基因组分析成本降至1000美元以下,加速了精准医疗的大众化。在韩国,SK生物制药开发的癫痫治疗药物“Cenobamate”在考虑患者个人基因变异的个性化处方中,疗效较传统药物提高了2.3倍。 制药行业的数字化转型也在加速。瑞士罗氏(Roche)在2025年向数字健康领域投资12亿美元,建立了基于AI的诊断平台,将癌症诊断准确度提高至92.7%。美国强生(Johnson & Johnson)通过其子公司Janssen投入8亿美元开发数字治疗药物,目前有7种数字治疗药物正在接受FDA审批。这些数字技术的引入使临床试验效率平均提高了35%,新药开发成本也比以往减少了28%。 生物制药制造领域的创新也在继续。通过引入连续制造技术,生产效率比传统批量制造方式提高了40%,制造成本降低了25%。三星生物制剂在仁川松岛建立的第四工厂引入了连续制造设施,将年生产能力从原来的24万升扩大到36万升。这是全球单一生物制药生产设施中规模最大的,全球制药公司对其委托生产订单激增。三星生物制剂2025年第三季度的销售额同比增长43.2%,达到9847亿韩元,营业利润率也达到28.3%,保持行业最高水平。 生物仿制药市场的增长也值得关注。全球生物仿制药市场在2025年已增长至287亿美元,预计到2030年将以15.2%的年均增长率增长。特别是随着高价生物药物专利的到期,对生物仿制药的需求激增。Celltrion的生物仿制药产品线预计在2025年实现累计销售额2.84万亿韩元,同比增长22.1%。特别是Celltrion的乳腺癌治疗生物仿制药“Herzuma”在欧洲市场的占有率达到34.2%,成为市场领先产品。 美国设有快速通道、突破性疗法认定、加速批准和优先审评等不同的加速项目。根据FDA的说明,优先审评的目标时限为6个月,标准审评为10个月,但这并不意味着所有罕见病药物或基因疗法的批准时间都统一缩短到6至9个月。Cures 2.0法案于2021年在美国众议院提出。 从投资的角度来看,生物技术行业仍然具有很高的增长潜力。2025年全球生物技术IPO市场总规模为184亿美元,同比增长67%。特别是AI驱动的新药开发企业的上市活动活跃,这些企业的平均市值达到12亿美元。在韩国,生物技术企业的KOSDAQ上市数量也在增加,2025年上市的生物企业总数为23家,远超去年的14家。这些新上市生物企业的平均市值为2340亿韩元,技术实力和成长性得到了认可。 然而,生物技术行业面临的挑战也不少。新药开发的高失败率仍然是主要风险因素,临床三期阶段的失败率仍然维持在45%。此外,AI驱动的新药开发中算法的可靠性和监管机构的审批标准不明确,存在不确定性。全球供应链的不稳定也影响着生物药品的制造,特别是在对中国原料药的依赖较高的情况下,地缘政治风险令人担忧。 生物技术行业的未来前景总体上是积极的。全球人口老龄化和慢性病增加带来的医疗需求扩大、AI技术的持续发展、政府的生物产业扶持政策等将成为增长动力。预计到2030年,全球生物技术市场将以12.4%的年均增长率增长至2.8万亿美元,韩国将占其中的3.2%,即896亿美元的市场份额。对于投资者来说,从长期角度来看,拥有技术实力和管线的优质生物技术企业将成为有吸引力的投资对象。…